论文部分内容阅读
2012年7月,美国FDA批准了Novartis公司的哺乳动物雷帕霉素靶的抑制剂依维莫司片剂(everolimus/Afinitor)一个新适应证,即联合甾体类芳香酶抑制剂依西美坦(exemestane/Aromasin)治疗在经非甾体类芳香酶抑制剂来曲唑(letrozole/Femara)或阿那曲唑(anastrozole/Arimidex)治疗后疾病复发或重又进展的绝经后妇女激素受体阳性、但表皮生长因子受体-2(HER2)阴性的进行性乳腺癌(以下简称为“激素受体阳性的进行性乳腺癌”)患者。
In July 2012, the United States FDA approved a new indication from Novartis mammalian everolimus inhibitor of everolimus (everolimus / Afinitor) that the combination of the steroidal aromatase inhibitor, Exemestane / Aromasin treatment of hormone receptor-positive postmenopausal women with recurrent or recurrent disease after treatment with the non-steroidal aromatase inhibitor letrozole / femara or anastrozole / Arimidex , But patients with epidermal growth factor receptor-2 (HER2) -negative progressive breast cancer (hereinafter referred to as “hormone receptor-positive progressive breast cancer”).